Watch Ticker

Editas Medicine, Inc. Common Stock

Go to Editas Medicine, Inc. Common Stock Website

$5.68

(%)

Live

Previous Close

$5.68

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$467.1 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform ba...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Editas Medicine, Inc. - Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.

Related tickers: EDIT.

Read Full Article

Editas Medicine, Inc. - Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications

Related tickers: EDIT.

Read Full Article

Trending Tickers

BTTX

XNAS

$0.01

(%)

OPRT

XNAS

$4.23

(%)

PALI

XNAS

$6.24

(%)

PRSO

XNAS

$1.42

(%)

ACRV

XNAS

$0.00

(%)